Madrigal Pharmaceuticals, Inc. (MDGL) News
Follow Madrigal Pharmaceuticals, Inc. (MDGL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 33 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Health Rounds: New blood test matches gold standard for liver disease diagnosis
By Nancy LapidHello Health Rounds readers! Today we feature two studies being presented at The Liver Meeting, the annual gathering of the American Association for the Study of Liver Diseases, which got underway on Thursd
COMMODITIES | Nov 05, 2026, 08:16 PM UTC
L
Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales
Madrigal Pharmaceuticals (MDGL) was on investors’ radar on Thursday, after the company reported encouraging real-world data for Rezdiffra, its lead drug for metabolic dysfunction-associated steatohepatitis (MASH), a seri
EQUITY | Nov 05, 2026, 05:25 PM UTC
M
MDGL Reports Fiscal Q3 Net Profit of -9689万美元
Net profit attributable to shareholders was -9689万美元, up 57.82% year over year. Basic EPS was -3.32美元.
EQUITY | Nov 04, 2026, 05:52 AM UTC
M
MDGL Shares Hit a Fresh 52-Week Low Amid Profitability Concerns
Madrigal Pharmaceuticals shares fell to a fresh 52-week low as investors weighed management’s warning that its first quarterly profit may not be durable amid commercial investments. Citi sees over 75% upside, according t
EQUITY | Nov 03, 2026, 08:15 PM UTC
M
Madrigal Pharmaceuticals Reports Quarterly Results
Madrigal Pharmaceuticals reported results for the quarter ended September 30.
EQUITY | Nov 03, 2026, 02:32 PM UTC
M
Madrigal Pharmaceuticals Reports Q3 Revenue of $431.27 Million, EPS of $1.83
Third-quarter revenue rose 50.1% year over year to $431.27 million. Net income was $55.44 million, versus a year-earlier net loss of $114.19 million; diluted EPS was $1.83 versus a loss of $4.01.
EQUITY | Nov 03, 2026, 02:11 PM UTC
M
Madrigal Pharmaceuticals swings to Q3 profit
Madrigal Pharmaceuticals shares rise after the company swung to a Q3 profit.
EQUITY | Nov 03, 2026, 01:28 PM UTC
M
Madrigal reports third-quarter profit
EQUITY | Nov 03, 2026, 01:28 PM UTC
M
Madrigal Reports Third-Quarter Revenue of $431.3 Million and Net Income of $55.4 Million
Madrigal reported third-quarter 2026 revenue up 50% year over year. Diluted earnings were $1.83 per share, compared with a loss of $4.01 per share a year earlier.
EQUITY | Nov 03, 2026, 01:15 PM UTC
M
Madrigal Pharmaceuticals Swings to Q3 Earnings as Revenue Rises
Madrigal Pharmaceuticals reported a Q3 earnings swing and higher revenue.
EQUITY | Nov 03, 2026, 12:56 PM UTC
M
Madrigal Q3 Rezdiffra Sales Jump as Company Posts First Profit
EQUITY | Nov 03, 2026, 12:23 PM UTC
L
Madrigal Pharmaceuticals Posts Q3 EPS of $1.83
EARNINGS | Nov 03, 2026, 12:07 PM UTC
M
Madrigal Pharmaceuticals Reports Q3 Product Revenue of $431.268 Million
EQUITY | Nov 03, 2026, 12:06 PM UTC
M
Madrigal Reports Third-Quarter 2026 Financial Results
Madrigal Pharmaceuticals reported Rezdiffra net sales of $431.3 million in the third quarter of 2026, year over year.
EQUITY | Nov 03, 2026, 12:01 PM UTC
L
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:51 PM UTC
L
Madrigal Pharmaceuticals Price Target Announced at $725.00/Share by Citigroup
Ratings actions from Benzinga: GMT) Madrigal Pharmaceuticals Initiated at Buy by CitigroupRatings actions from Benzinga
NEWS | Sep 23, 2026, 03:13 PM UTC
L
MDGL - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGL - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 08:05 PM UTC
M
MDGL reports Q2 sales of $364 million
MDGL said Q2 sales reached $364 million. The company also reported over 50,000 patients treated and described market uptake alongside a pipeline advancing.
EARNINGS | Sep 10, 2026, 07:03 PM UTC
L
Madrigal Pharmaceuticals to participate in 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals says it will take part in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT. The presentation will be webcast live.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
MDGL to participate in 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals will participate in the 2026 Cantor Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
Madrigal Pharmaceuticals grants inducement awards under Nasdaq Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 20, 2026, 08:05 PM UTC
L
MDGL Appoints John C. Reed to Board
MDGL appoints John C. Reed, M.D., Ph.D., to its Board of Directors
MNA | Aug 12, 2026, 12:00 PM UTC
H
MDGL upgraded to Outperform at Wolfe
MDGL upgraded to Outperform with $605 price target
EQUITY | Aug 04, 2026, 09:44 AM UTC
H
Barclays Raises MDGL PT to $962
Barclays raises price target for MDGL
EQUITY | Aug 03, 2026, 09:59 AM UTC
L
MDGL Seen As Buying Opportunity
MDGL shares seen as buying opportunity
EARNINGS | Jul 31, 2026, 01:01 PM UTC
H
Madrigal Q2 Revenue Surges 71%
Madrigal revenue surges 71% year-over-year
EQUITY | Jul 30, 2026, 12:37 PM UTC
L
MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating I
MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating Income $-56.308M, Q2 EPS $-1.99
EARNINGS | Jul 30, 2026, 11:04 AM UTC
L
MDGL - Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
MDGL - Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
MDGL Initiated Overweight W/$685.00 PT at Wells Fargo
MDGL Initiated Overweight W/$685.00 PT at Wells Fargo
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
MDGL initiated with an Overweight at WFC w/ $685 PT
MDGL initiated with an Overweight at WFC w/ $685 PT
EQUITY | Jul 27, 2026, 09:50 AM UTC
L
Reported Earlier, Ribo And Madrigal Achieve First Candidate Drug Nomination Milestone Within Their siRNA Partnership For Liver Disease
Reported Earlier, Ribo And Madrigal Achieve First Candidate Drug Nomination Milestone Within Their siRNA Partnership For Liver Disease
EQUITY | Jul 02, 2026, 06:54 AM UTC